Mercer Global Advisors
DRUG

Mercer Global Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Mercer Global Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Buy
+209
New +$16.4K ﹤0.01% 4972

Other funds holding DRUG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return

Mercer Global Advisors's DRUG Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 209 shares worth $14.7K. The stake represents ﹤0.01% of the portfolio and ranks #4972 among its holdings.

52 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Mercer Global Advisors held 209 shares of Bright Minds Biosciences worth $14.7K as of Q2 2026.
  • Bright Minds Biosciences was a new Mercer Global Advisors position in Q2 2026.
  • Bright Minds Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4972 holding.
  • 52 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.